Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
GlobalData on MSN2d
Pfizer pitches pipeline priorities in oncology and obesity at JP Morgan 2025
CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in ...
pharmaphorum9d
Pfizer promotes potential CEO successor Bourla
Pfizer has promoted Albert Bourla, seen as a likely successor to incumbent CEO Ian Read, to the newly-created role of chief operating officer. The move could help Read focus on long-term ...
BioSpace2d
Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
FiercePharma2d
JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales
Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.
Yahoo2d
Pfizer CEO Is Optimistic Ahead of the Trump Administration. ‘The Opportunities Outweigh the Risks.’
Pfizer CEO Albert Bourla said he had spoken to Robert F. Kennedy Jr. in an effort to “find opportunities on things we can agree.” ...